HuGE Literature Finder
Records 1-13
|
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Cancer science 2020 Nov . Sakai Kazuko, Tsuboi Masahiro, Kenmotsu Hirotsugu, Yamanaka Takeharu, Takahashi Toshiaki, Goto Koichi, Daga Haruko, Ohira Tatsuo, Ueno Tsuyoshi, Aoki Tadashi, Nakagawa Kazuhiko, Yamazaki Koji, Hosomi Yukio, Kawaguchi Koji, Okumura Norihito, Takiguchi Yuichi, Sekine Akimasa, Haruki Tomohiro, Yamamoto Hiromasa, Sato Yuki, Akamatsu Hiroaki, Seto Takashi, Saeki Sho, Sugio Kenji, Nishio Makoto, Okabe Kazunori, Yamamoto Nobuyuki, Nishio Kazu |
|
Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Feb . Aggarwal Charu, Thompson Jeffrey C, Chien Austin L, Quinn Katie J, Hwang Wei-Ting, Black Taylor A, Yee Stephanie S, Christensen Theresa, LaRiviere Michael J, Silva Benjamin A, Banks Kimberly C, Nagy Rebecca J, Helman Elena, Berman Abigail T, Ciunci Christine A, Singh Aditi P, Wasser Jeffrey S, Bauml Joshua M, Langer Corey J, Cohen Roger B, Carpenter Erica |
|
The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients.
Frontiers in oncology 2020 10 726. Liu Shaokun, Huang Tanxiao, Liu Ming, He Wenlong, Zhao YingShen, Yang Lizhen, Long Yingjiao, Zong Dandan, Zeng Huihui, Liu Yuanyuan, Liao Wenting, Duan Jingxian, Gong Subo, Chen Shi |
|
Association between Certain NSCLC Driver Mutations and Predictive Markers for Chemotherapy or PD-(L)1 Inhibition.
Cancer science 2019 Apr . Liang Wenhua, Guo Minzhang, Pan Zhenkui, Cai Xiuyu, Li Caichen, Zhao Yi, Liang Hengrui, Yang Haiying, Wang Zhen, Chen Wenting, Xu Chuhong, Yang Xinyun, Sun Jianyu, He Ping, Gu Xia, Yin Weiqiang, He Jianxi |
|
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Molecular cancer 2018 Apr 17 (1): 81. Liu Liang, Ruiz Jimmy, O'Neill Stacey S, Grant Stefan C, Petty W Jeffrey, Yang Meng, Chen Kexin, Topaloglu Umit, Pasche Boris, Zhang W |
|
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) 2017 Sep 111 23-29. Labbé Catherine, Cabanero Michael, Korpanty Grzegorz J, Tomasini Pascale, Doherty Mark K, Mascaux Céline, Jao Kevin, Pitcher Bethany, Wang Rick, Pintilie Melania, Leighl Natasha B, Feld Ronald, Liu Geoffrey, Bradbury Penelope Ann, Kamel-Reid Suzanne, Tsao Ming-Sound, Shepherd Frances |
|
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Dec . Zer Alona, Ding Keyue, Lee Siow Ming, Goss Glenwood D, Seymour Lesley, Ellis Peter M, Hackshaw Allan, Bradbury Penelope A, Han Lei, O'Callaghan Christopher J, Tsao Ming-Sound, Shepherd Frances |
|
Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
Lung cancer (Amsterdam, Netherlands) 2014 Nov 86 (2): 164-9. Chao Liu, Yi-Sheng Huang, Yu Chen, Li-Xu Yan, Xin-Lan Luo, Dong-Lan Luo, Jie Chen, Yi-Lon Wu, Hui Liu Y |
|
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Sep 20 (17): 4647-59. Molina-Vila Miguel A, Bertran-Alamillo Jordi, Gascó Amaya, Mayo-de-las-Casas Clara, Sánchez-Ronco María, Pujantell-Pastor Laia, Bonanno Laura, Favaretto Adolfo G, Cardona Andrés F, Vergnenègre Alain, Majem Margarita, Massuti Bartomeu, Morán Teresa, Carcereny Enric, Viteri Santiago, Rosell Rafa |
|
The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2014 Sep 9 (9): 1363-9. Izar Benjamin, Zhou Haiyu, Heist Rebecca S, Azzoli Christopher G, Muzikansky Alona, Scribner Emily E F, Bernardo Lindsay A, Dias-Santagata Dora, Iafrate Anthony J, Lanuti Micha |
|
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Lung cancer (Amsterdam, Netherlands) 2014 Mar 83 (3): 383-8. Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon J P, Soria J |
|
Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
Medical science monitor : international medical journal of experimental and clinical research 2014 20 2666-76. Zhang Wen-Qian, Li Tong, Li H |
|
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data.
In vivo (Athens, Greece) 0 34 (4): 2009-2014. Santarpia Mariacarmela, Altavilla Giuseppe, Borsellino Nicolo, Girlando Andrea, Mancuso Gianfranco, Pergolizzi Stefano, Piazza Dario, Pontoriero Antonio, Valerio Maria Rosaria, Gebbia Vittor |
- Page last reviewed:Oct 1, 2020
- Page last updated:Feb 24, 2021
- Content source: